
    
      This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical
      activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with
      gemcitabine in relapsed or refractory osteosarcoma.
    
  